Pfizer Inc. (NYSE:PFE – Get Rating) declared a quarterly dividend on Friday, December 9th, RTT News reports. Investors of record on Friday, January 27th will be given a dividend of 0.41 per share by the biopharmaceutical company on Friday, March 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date is Thursday, January 26th. This is a boost from Pfizer’s previous quarterly dividend of $0.40.
Pfizer has raised its dividend payment by an average of 3.3% per year over the last three years and has raised its dividend every year for the last 12 years. Pfizer has a dividend payout ratio of 38.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $4.50 per share next year, which means the company should continue to be able to cover its $1.64 annual dividend with an expected future payout ratio of 36.4%.
Pfizer Trading Down 0.6 %
PFE opened at $44.71 on Wednesday. Pfizer has a one year low of $41.44 and a one year high of $56.32. The stock has a market capitalization of $250.97 billion, a PE ratio of 8.60, a P/E/G ratio of 1.11 and a beta of 0.67. The business’s 50 day moving average price is $49.68 and its 200 day moving average price is $48.06. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.37 and a current ratio of 1.59.
Hedge Funds Weigh In On Pfizer
Large investors have recently bought and sold shares of the stock. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter valued at $29,000. Red Wave Investments LLC boosted its stake in Pfizer by 33.6% in the first quarter. Red Wave Investments LLC now owns 5,124 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 1,288 shares in the last quarter. Front Street Capital Management Inc. boosted its stake in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares in the last quarter. RB Capital Management LLC boosted its stake in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 341 shares in the last quarter. Finally, Navis Wealth Advisors LLC boosted its stake in Pfizer by 19.8% in the first quarter. Navis Wealth Advisors LLC now owns 6,050 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.
Wall Street Analysts Forecast Growth
PFE has been the topic of a number of research analyst reports. UBS Group set a $55.00 target price on Pfizer in a research report on Wednesday, January 18th. Barclays upped their price objective on Pfizer from $44.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 2nd. Morgan Stanley upped their price objective on Pfizer from $51.00 to $53.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 14th. JPMorgan Chase & Co. set a $50.00 price objective on Pfizer in a research report on Wednesday, January 18th. Finally, SVB Leerink upped their price objective on Pfizer from $48.00 to $49.00 and gave the stock a “market perform” rating in a research report on Thursday, November 3rd. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $53.00.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.